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bd) (Form + Bud) given concurrently in adult patients
with moderate-to-severe asthma. METHODS: The
Markov model for the Polish Health care context was
based on clinical data from the literature (data from ran-
domised, double blind head-to-head comparison of SFC
and Form + Bud treatments in adults) and local data on
Health care resource utilisation and unit costs. Given
their clinical and economic importance, asthma exacer-
bations were a central consideration in the development
of the model. The outcome measure was number of suc-
cessfully controlled weeks (SCW) during the study period.
Only direct medical costs were analysed. The payer’s per-
spective and time horizon of 12 weeks were adopted.
Probabilistic sensitivity analysis was used to examine the
uncertainty in the cost-effectiveness results. It was
assumed that price of SFC is equal its components prices.
RESULTS: Running the model over 12-week period using
transition probabilities derived from RCT demonstrated
that treatment with SFC in comparison to the treatment
with Form + Bud resulted in a higher proportion of SCW
per patient (2.68 [CI 95%: 2.29–3.13] vs. 2.44 [CI 95%:
2.05–2.85]). SFC was also the less costly treatment, due
primarily to lower hospitalization and drug costs. Mean
weekly direct asthma management costs was 58.39 PLN
(CI 95%: 53.54–65.36) in SFC per treated patient and
72.42 PLN (CI 95%: 66.94–80.39) per Form + Bud
treated patient. Probabilistic sensitivity analysis showed
that in all cases SFC was the dominant strategy (more
effective and less costly). CONCLUSION: Since SFC
resulted in a better effect at a lower cost, this strategy 
was considered to be dominant for Polish patients with
moderate-to-severe asthma.
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OBJECTIVE: Asthma ranks ﬁrst among serious chronic
diseases affecting children and is reported to be the third
leading cause of hospitalization for children. This study
examines the resource use and costs of hospital care for
children and adolescents (age <= 17 years) admitted for
asthma in California and Massachusetts. METHODS:
Patient-level 2000 hospital discharge data from both
states were examined using ICD-9 diagnosis codes
(493.00–493.02, 493.90–493.92) to identify those admit-
ted with a principal diagnosis of asthma. These databases
were used to examine demographics and to develop hos-
pital costs, length of stay (LOS), physician visit proﬁles,
dispositions, and readmissions. Cost estimates include
accommodations, ancillary and physician services and are
reported in 2003 US$. Hospital charges were adjusted by
means of a 0.61 cost-to-charge ratio. RESULTS: Of the
10,488 cases identiﬁed: 59% were male; mean age was
6.6 years (median: 5.5, 79% were <=10 years); 51% were
admitted through Emergency Room, and 13% spent time
in special care units. Race/ethnicity was reported as 
Hispanic for the majority of patients (37%), followed 
by white (27%), black (27%), Asian (5%), and Other/
Unknown (4%). Mean LOS was 2.4 days (median: 2,
range: 1–142). Mean cost per stay was $5,045 (median:
$3,319, range: $194–$687,177). Hospital case fatality
rate was <1%. Among survivors, >99% went home,
1.5% with home health care. Most patients (89%) had
only 1 admission during the year; however 11% had at
least 1 readmission (range: 1–9). Managed care organi-
zations were the responsible payer for most cases (63%),
followed by Medicaid (27%). CONCLUSIONS: The cost
of a hospital stay is considerable and represents a sub-
stantial economic consequence of asthma. The majority
of patients were recorded as Hispanic, however, this is
likely a reﬂection of the states used and should not be
interpreted as increased frequency of asthma in Hispanic
children overall.
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OBJECTIVE: To compare the feasibility, reliability, valid-
ity and sensitivity to change of the Spanish version of the
Juniper Quality of Life Questionnaire (AQLQ), Juniper
Mini Asthma Quality of Life Questionnaire (Mini-
AQLQ) and Marks Asthma Quality of Life Questionnaire
(Marks-AQLQ) for use in clinical practice. METHODS:
Eight hundred seventy-eight patients, with a diagnosis of
mild to moderate asthma, were randomly assigned to
receive one of the 3 questionnaires. Montelukast was
added to the patients with uncontrolled asthma. Feasibil-
ity was assessed using mean time of administration and
percentage of missing responses. Internal consistency and
reliability was assessed using Cronbach’s alpha and the
intraclass correlation coefﬁcient (ICC). Construct validity
was assessed by correlating questionnaire scores with
EuroQoL-5D scores and symptoms. Responsiveness was
assessed by calculating the standardized effect size (SES).
RESULTS: Mean administration time was 7, 8 and 13
minutes for Mini-AQLQ, Marks-AQLQ and AQLQ
respectively. On the Mini-AQLQ and Marks-AQLQ 3.3
and 3.8% patients had missing responses compared with
11.1% on the AQLQ. For Mini-AQLQ, Marks-AQLQ
and AQLQ Cronbach’s alpha were 0.85, 0.90 and 0.91
respectively and ICC were 0.63, 0.74 and 0.78. In uni-
